Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma

Autor: Pietro Leoni, Laura Corvatta, Antonio Palumbo, Massimo Offidani, Maria-Novella Piersantelli, Sara Bringhen, Patrizia Falco, Monica Marconi, Ilaria Avonto, Mario Boccadoro, Claudia Polloni
Rok vydání: 2007
Předmět:
Zdroj: European journal of haematology. 78(4)
ISSN: 0902-4441
Popis: Objectives: Nearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy. Several salvage therapies have been explored, but the optimal combination regimen has not been defined. We performed a case-matched study comparing patients with relapsed/refractory MM receiving thalidomide–dexamethasone alone or the combination thalidomide–dexamethasone–liposomal pegylated doxorubicin. Methods: Forty-seven patients received thalidomide (100 mg/d), dexamethasone (40 mg p.o. on days 1–4 and 9–12), and pegylated liposomal doxorubicin (40 mg/m2 on day 1 every 28 d) (ThaDD). Their clinical outcome was compared with that of 47 pair mates selected from patients treated at relapse with thalidomide (100 mg/d) and dexamethasone (40 mg p.o. on days 1–4) (Thal–Dex) and matched for age, β2-microglobulin and previous therapy. Results and conclusions: Overall response rate was significantly higher in ThaDD group (92% vs. 63.5%; P
Databáze: OpenAIRE